Plavix, Iscover(clopidogrel)
DuoCover, DuoPlavin, Iscover, Plavix (clopidogrel) is a small molecule pharmaceutical. Clopidogrel was first approved as Plavix on 1997-11-17. It has been approved in Europe to treat acute coronary syndrome, atrial fibrillation, myocardial infarction, peripheral vascular diseases, and stroke. It is known to target P2Y purinoceptor 12.
Download report
Favorite
Searched
BMS
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Plavix (generic drugs available since 2008-01-14)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Clopidogrel bisulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PLAVIX | Sanofi | N-020839 RX | 1997-11-17 | 2 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| clopidogrel | ANDA | 2023-06-12 |
| plavix | New Drug Application | 2021-03-05 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
641 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | 7 | 15 | 22 | 88 | 22 | 149 | |
| Acute coronary syndrome | D054058 | EFO_0005672 | 6 | 10 | 22 | 42 | 8 | 87 | |
| Healthy volunteers/patients | — | 41 | 1 | — | 4 | 2 | 48 | ||
| Myocardial infarction | D009203 | EFO_0000612 | I21 | 1 | 5 | 14 | 19 | 4 | 41 |
| Stroke | D020521 | EFO_0000712 | I63.9 | 2 | 5 | 11 | 13 | 4 | 32 |
| Percutaneous coronary intervention | D062645 | 1 | 5 | 8 | 11 | 6 | 29 | ||
| Coronary disease | D003327 | — | 1 | 2 | 18 | 4 | 24 | ||
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | 6 | 14 | 1 | 22 |
| Ischemic stroke | D000083242 | 2 | 4 | 8 | 5 | 5 | 21 | ||
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | 2 | 3 | 11 | 2 | 20 |
Show 69 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial arteriosclerosis | D002537 | EFO_1000860 | I67.2 | — | 1 | 3 | — | — | 3 |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | 1 | 2 | — | — | 3 |
| Cerebral hemorrhage | D002543 | — | 1 | 1 | — | — | 2 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | 1 | — | 1 | 2 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | 1 | — | — | 1 |
| Ventricular outflow obstruction | D014694 | EFO_1001448 | — | — | 1 | — | — | 1 | |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | 1 | — | — | 1 |
| Middle cerebral artery infarction | D020244 | EFO_1001045 | G46.0 | — | — | 1 | — | — | 1 |
| Thrombophilia | D019851 | D68.59 | — | — | 1 | — | — | 1 | |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | 1 | — | — | 1 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | 1 | 1 | — | — | — | 2 | ||
| Hiv | D006678 | O98.7 | 1 | 1 | — | — | — | 2 | |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | — | 1 |
| Embolism and thrombosis | D016769 | — | 1 | — | — | — | 1 | ||
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
| Cognition disorders | D003072 | — | 1 | — | — | — | 1 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | — | 1 |
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Polycythemia vera | D011087 | D45 | — | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | HP_0003124 | 1 | — | — | — | 1 | 2 | |
| Therapeutic equivalency | D013810 | 2 | — | — | — | — | 2 | ||
| Pharmacokinetics | D010599 | 2 | — | — | — | — | 2 | ||
| Fasting | D005215 | EFO_0002756 | 2 | — | — | — | — | 2 | |
| Hemostasis | D006487 | 2 | — | — | — | — | 2 | ||
| Hyperlipoproteinemia type v | D006954 | Orphanet_70470 | E78.3 | 1 | — | — | — | — | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-eluting stents | D054855 | — | — | — | — | 2 | 2 | ||
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | — | — | — | 2 | 2 |
| Asymptomatic diseases | D058070 | — | — | — | — | 2 | 2 | ||
| Coronary occlusion | D054059 | I21 | — | — | — | — | 1 | 1 | |
| Cerebral amyloid angiopathy | D016657 | EFO_0006790 | I68.0 | — | — | — | — | 1 | 1 |
| Surgical blood loss | D016063 | — | — | — | — | 1 | 1 | ||
| Hyperuricemia | D033461 | — | — | — | — | 1 | 1 | ||
| Hemolysis | D006461 | — | — | — | — | 1 | 1 | ||
| Endotoxemia | D019446 | — | — | — | — | 1 | 1 | ||
| Secondary prevention | D055502 | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | CLOPIDOGREL |
| INN | clopidogrel |
| Description | Clopidogrel is a thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks. It has a role as a platelet aggregation inhibitor, an anticoagulant and a P2Y12 receptor antagonist. It is a thienopyridine, a member of monochlorobenzenes and a methyl ester. It is functionally related to a ticlopidine. |
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1 |
Identifiers
| PDB | — |
| CAS-ID | 113665-84-2 |
| RxCUI | 32968 |
| ChEMBL ID | CHEMBL1771 |
| ChEBI ID | 37941 |
| PubChem CID | 60606 |
| DrugBank | DB00758 |
| UNII ID | A74586SNO7 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
P2RY12
P2RY12
Organism
Homo sapiens
Gene name
P2RY12
Gene synonyms
HORK3
NCBI Gene ID
Protein name
P2Y purinoceptor 12
Protein synonyms
ADP-glucose receptor, ADPG-R, G-protein coupled receptor SP1999, Gi-coupled ADP receptor HORK3, P2T(AC), P2Y(AC), P2Y(ADP), P2Y(cyc), P2Y12 platelet ADP receptor, purinergic receptor P2RY12, purinergic receptor P2Y, G-protein coupled, 12, putative G-protein coupled receptor, SP1999
Uniprot ID
Mouse ortholog
P2ry12 (70839)
P2Y purinoceptor 12 (Q9CPV9)
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
|---|---|---|---|---|
| VCV000638797 | CYP2C19, Pro227= | drug response | 2019-06-17 | P |
| VCV000638790 | CYP2C19, LOC110599570, Met1Val | drug response | 2019-06-17 | P |
| VCV000638258 | CYP2C19, Arg433Trp | drug response | 2019-06-17 | P |
| VCV000638257 | CYP2C19 | drug response | 2019-06-17 | P |
| VCV000638256 | CYP2C19, Arg132Gln | drug response | 2019-06-17 | P |
| VCV000638255 | CYP2C19, Met1Val | drug response | 2019-06-17 | P |
| VCV000638254 | CYP2C19, Trp120Arg | drug response | 2019-06-17 | P |
| VCV000638253 | CYP2C19, Trp212Ter | drug response | 2019-06-17 | P |
| VCV000638251 | CYP2C19, LOC110599570 | drug response | 2019-06-17 | P |
| VCV000638207 | CYP2C19, LOC110599570 | drug response | 2019-06-17 | P |
Show 46 more
Financial
Plavix - Bristol Myers Squibb
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Plavix - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 40,523 documents
View more details
Safety
Black-box Warning
Black-box warning for: Clopidogrel, Plavix
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,941 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more